Clinical Trials
13 trialsNCT04557059 2026-06-05
PRIMORDIUM
Janssen Pharmaceutica N.V., Belgium
Phase 3 Active not recruiting
NCT00945009 2026-06-03
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
Children's Oncology Group
Phase 3 Completed
NCT06770582 2026-06-03
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03775265 2026-05-29
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02177292 2026-05-26
SIB
Medical College of Wisconsin
Phase NA Active not recruiting
NCT07607431 2026-05-26
AWARE
Rigshospitalet, Denmark
Active not recruiting
NCT02799706 2026-05-22
PEGASUS
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Active not recruiting
NCT04216290 2026-05-22
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03274687 2026-05-20
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
NRG Oncology
Phase 3 Completed
NCT03987386 2026-05-20
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
NCT04879940 2026-05-20
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT07477626 2026-05-19
RADVAN
Sun Yat-sen University
Phase 3 Active not recruiting
NCT04947254 2026-05-15
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting